Gene · 64115
Papers2,513
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 2,513
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target. | Front Cell Dev Biol | 2023 | 38264357 | PubTator, text mining | PubMed |
| Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies. | Cancer Drug Resist | 2023 | 38263984 | PubTator, text mining | PubMed |
| Harnessing Immunity to Treat Advanced Thyroid Cancer. | Vaccines (Basel) | 2023 | 38250858 | PubTator, text mining | PubMed |
| Spatial profiling of the placental chorioamniotic membranes reveals upregulation of immune checkpoint proteins during Group B Streptococcus infection in a nonhuman primate model. | Front Cell Infect Microbiol | 2023 | 38239507 | PubTator, text mining | PubMed |
| Soluble Forms of Immune Checkpoints and Their Ligands as Potential Biomarkers in the Diagnosis of Recurrent Pregnancy Loss-A Preliminary Study. | Int J Mol Sci | 2023 | 38203670 | PubTator, text mining | PubMed |
| YTHDF1 in Tumor Cell Metabolism: An Updated Review. | Molecules | 2023 | 38202722 | PubTator, text mining | PubMed |
| A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors. | Front Immunol | 2023 | 38152397 | PubTator, text mining | PubMed |
| VISTA as a prospective immune checkpoint in gynecological malignant tumors: A review of the literature. | Open Med (Wars) | 2023 | 38152334 | PubTator, text mining | PubMed |
| Unlocking molecular mechanisms and identifying druggable targets in matched-paired brain metastasis of breast and lung cancers. | Front Immunol | 2023 | 38149244 | PubTator, text mining | PubMed |
| Alternative immune checkpoints in immunoregulatory profile of cancer stem cells. | Heliyon | 2023 | 38144305 | PubTator, text mining | PubMed |
| Insights into the Tumor Microenvironment-Components, Functions and Therapeutics. | Int J Mol Sci | 2023 | 38139365 | PubTator, text mining | PubMed |
| Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma. | Int J Mol Sci | 2023 | 38139110 | PubTator, text mining | PubMed |
| Evaluation of Chelator-to-Antibody Ratio on Development of 89Zr-iPET Tracer for Imaging of PD-L1 Expression on Tumor. | Int J Mol Sci | 2023 | 38138961 | PubTator, text mining | PubMed |
| CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy. | Biomedicines | 2023 | 38137547 | PubTator, text mining | PubMed |
| siRNA-Mediated B7H7 Knockdown in Gastric Cancer Lysate-Loaded Dendritic Cells Amplifies Expansion and Cytokine Secretion of Autologous T Cells. | Biomedicines | 2023 | 38137433 | PubTator, text mining | PubMed |
| Challenges and Future Directions in the Management of Tumor Mutational Burden-High (TMB-H) Advanced Solid Malignancies. | Cancers (Basel) | 2023 | 38136385 | PubTator, text mining | PubMed |
| The Current Treatment Landscape of Malignant Pleural Mesothelioma and Future Directions. | Cancers (Basel) | 2023 | 38136353 | PubTator, text mining | PubMed |
| Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy. | Cancers (Basel) | 2023 | 38136333 | PubTator, text mining | PubMed |
| Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies. | Cancers (Basel) | 2023 | 38136311 | PubTator, text mining | PubMed |
| Prognostic Implications of LRP1B and Its Relationship with the Tumor-Infiltrating Immune Cells in Gastric Cancer. | Cancers (Basel) | 2023 | 38136305 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64115/papers?page=16